Vise Technologies Inc. Purchases Shares of 1,595 Cencora, Inc. (NYSE:COR)

Vise Technologies Inc. bought a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,595 shares of the company's stock, valued at approximately $358,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COR. Hickory Asset Management Inc. acquired a new stake in Cencora in the fourth quarter valued at approximately $572,000. Sylvest Advisors LLC bought a new stake in Cencora in the fourth quarter worth about $1,105,000. Vontobel Holding Ltd. raised its position in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after purchasing an additional 1,995 shares during the period. Milestone Asset Management LLC raised its position in shares of Cencora by 430.2% in the fourth quarter. Milestone Asset Management LLC now owns 5,461 shares of the company's stock valued at $1,227,000 after purchasing an additional 4,431 shares during the period. Finally, Portfolio Design Labs LLC grew its stake in Cencora by 76.9% during the fourth quarter. Portfolio Design Labs LLC now owns 11,032 shares of the company's stock valued at $2,479,000 after acquiring an additional 4,794 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of research reports. Wells Fargo & Company boosted their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. UBS Group upped their price objective on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Robert W. Baird upped their target price on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Finally, Morgan Stanley set a $288.00 price objective on shares of Cencora in a research report on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Cencora has an average rating of "Moderate Buy" and a consensus target price of $301.18.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the sale, the chairman now directly owns 315,913 shares of the company's stock, valued at $89,027,442.53. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. This represents a 21.96% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,223 shares of company stock valued at $12,369,767. Insiders own 10.80% of the company's stock.

Cencora Trading Up 0.3%

COR traded up $0.80 on Friday, hitting $291.49. The company had a trading volume of 3,890,003 shares, compared to its average volume of 1,537,835. The company's fifty day moving average price is $284.83 and its 200 day moving average price is $258.61. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The firm has a market cap of $56.50 billion, a P/E ratio of 41.46, a PEG ratio of 1.31 and a beta of 0.60. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.80 earnings per share. As a group, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's payout ratio is 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.